SEC Tracker
Get the app

Femasys FEMY

Femasys FY 2025: revenue $2.3M, up 41%; diluted EPS −$9.40

Form
10-K
Filed
Period
Importance
Notable

Key figures from this report

These are the numbers Femasys reported for the year ended Dec 31, 2025, as tagged in the filing’s XBRL data, each against the year before. A plain-English reading of this report is not written yet.

  1. Revenue$2.3M+41% from $1.6M in FY 202410-K income statement, on EDGAR
  2. Net income−$18.6MAgainst −$18.8M in FY 202410-K income statement, on EDGAR
  3. Diluted EPS−$9.40Against −$17.00 in FY 2024. Split-adjusted, as the tables show it; the filing reported −$0.4710-K income statement, on EDGAR
  4. Cash and cash equivalents$9.3M+168% from $3.5M in FY 202410-K balance sheet, on EDGAR
  5. Cash from operations−$18.7MAgainst −$19.4M in FY 202410-K cash flow statement, on EDGAR

Every year in the financial tables

View on EDGAR

Open in the app

Get an email when Femasys files

Only major filings: results, leadership changes, listing notices and other major events, each with the plain-English summary when we have one or the key facts and the EDGAR link. Routine insider filings never email. Confirm once; unsubscribe in one click.

Similar companies

Same SIC code (3841) and public float under $300M, nearest public float first, as each company reports it on its annual report cover.

  1. DarioHealth DRIO public float $28M, Jun 30, 2025
  2. Cerenome CNSY public float $32M, Jun 30, 2025
  3. Nephros NEPH public float $27M, Jun 30, 2025
  4. RenovoRx RNXT public float $27M, Jun 30, 2025
  5. Neuroone Medical Technologies NMTC public float $26M, Mar 31, 2025, over 18 months old